EVERSANA Builds on Commitment to “Pharmatize” AI with Amazon Web Services, Introduces Transformative Medical & Regulatory Review Solution


Building on a promise to “pharmatize” artificial intelligence (AI) across the life sciences sector, EVERSANA®, a leading provider of commercial services to the global life sciences industry, today announced the first of several new generative AI-based innovations on Amazon Web Services (AWS) to drive greater efficiency and business value for companies and ultimately improved patient outcomes.

The first solution, developed by EVERSANA leveraging AWS and AWS Partner TensorIoT, addresses a time-consuming and error-prone process in the industry – medical and regulatory content approvals.

The traditional way that brands and marketing teams ensure the accuracy and compliance of claims included in branded materials is critical but cumbersome, requiring significant investment in resources and time. The complexity of this process across healthcare is a primary barrier to delivering personalized and timely customer experiences.

The new offering from EVERSANA automates the content fact-checking and approval portion of the process leveraging generative AI and Natural Language Processing (NLP) services from AWS. Using Amazon Bedrock and Amazon Textract, disparate data sets are aggregated and tagged, reducing time and effort throughout the process while providing an accurate and expedited user experience.

“Pharmatizing AI in the life sciences industry is about leveraging technology to optimize and accelerate common processes that are desperate for innovation and transformation,” said Jim Lang, CEO, EVERSANA. “As we came together with AWS, it became clear we could make a real impact in the medical and regulatory review process for branded materials. The team has done amazing work in short order to bring a solution to our industry that will bring unmatched accuracy and speed and ultimately, benefit patients.”

The new offering is the first of several new EVERSANA solutions in development leveraging AWS. Other projects underway include:

  • Field and patient assistance solutions, like chatbots, to automate mundane tasks, provide more accurate responses and improve user experiences.
  • Disease and product education content generation and personalization services, to help life sciences brands improve engagement with and education for both HCPs and patients.

Leaders from AWS and EVERSANA will be at the AWS re:Invent Conference, November 27-30, 2023, in Las Vegas.


EVERSANA Unveils EVERSANA ORCHESTRATE, Life Science Industry’s First End-to-End Omnichannel Solution Driving Brand Connectivity and Activating Commercialization Services


EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today announced the launch of EVERSANA ORCHESTRATE™, the life science industry’s first end-to-end omnichannel solution focused on amplifying brand impact. It orchestrates “next best experience” commercialization services to simultaneously drive sales and patient outcomes.

Informed by a global omnichannel advisory council of more than 20 pharmaceutical leaders and 40 subject matter experts, EVERSANA ORCHESTRATE leverages artificial intelligence (AI) and machine learning (ML) to apply a deep understanding of patient and provider needs. The solution aggregates and synthesizes pivotal data points to predict and capitalize on brand opportunities while reducing market waste. It serves as a seamless router of actionable data and deep insights across both personal and non-personal channels, providing brands with optimal touchpoint orchestration.

EVERSANA ORCHESTRATE transcends the limitations of traditional omnichannel solutions by activating EVERSANA’s full commercialization services, including global agency network solutions, patient support services and field deployment teams, including promotional, medical, and market access solutions. The end-to-end approach bridges strategy, process, and technology to the omnichannel needs of marketing and sales teams across the healthcare industry. The result provides highly engaging experiences that amplify impact through sales, efficiencies, and stakeholder satisfaction.

“Omnichannel is a buzzword we’ve heard time and time again across our industry. However, the reality is most omnichannel solutions today are one-dimensional, solely focused on HCP engagement and capabilities,” said Jim Lang, CEO, EVERSANA. “Clients deserve a better way to connect the dots across the care journey. Through the investment we’ve made in strategy, processes, and technology, EVERSANA ORCHESTRATE goes beyond the right message at the right time, and finally addresses the need for commercialization simplicity, success and business impact.”

EVERSANA ORCHESTRATE is powered by the EVERSANA ORCHESTRATE Engine™, a proprietary tool that leverages, machine learning (ML) and ACTICS®, EVERSANA’s enterprise-wide data, analytics, and technology ecosystems. Complementing existing marketing technology platforms like Adobe, Salesforce and Veeva, it amplifies impact by optimizing customer experiences across all channels through deep customer understanding. Driving the highest possible engagement the engine delivers HCP identification, affinity preferences, journey selection, share of voice throttling, and touchpoint optimization all powered by AI.

“Now more than ever, the life science industry needs a fresh approach to what omnichannel is all about,” added Lang. “While we offer omnichannel capabilities like many others, our true differentiator remains our ability to be a strategic partner to our clients, keeping the complex simple and connecting brands with their customers across all touchpoints of their unique journeys and ever-changing needs.”

To learn more about EVERSANA ORCHESTRATE and request a demo, visit eversana.com/ORCHESTRATE.